SARAH
Regimen
- Experimental
- SIRT with yttrium-90 resin microspheres
- Control
- sorafenib 400 mg BID
Population
Locally advanced or inoperable hepatocellular carcinoma (French multicentre)
Key finding
mOS 8.0 vs 9.9 mo (HR 1.15, P=0.18) — Y-90 SIRT NOT superior to sorafenib in locally advanced HCC. Negative trial for SIRT as systemic alternative.
Source: PMID 29107679